What is AMGN's House Rating?

AMGN scores 58 out of 100 (grade C) as of 2026-10-16, ranking #50 of 150 Health Care stocks we cover.

What do analysts say about AMGN?

ThetaGrade's analyst-sentiment pillar for AMGN scores 17/100 against its sector peers, which we read as negative. This is our own derived score; we do not republish individual analyst ratings, counts or targets.

When does AMGN report earnings next?

AMGN's next earnings report is estimated for about 2026-11-03 (window 2026-10-28 to 2026-11-09), based on its past SEC 8-K earnings filings. This is an estimate, not a company-confirmed date.

ThetaGrade does not give personal advice. The House Rating is an educational, rules-based summary of public data; see the methodology for how it is built.

AMGN Amgen

Health Care · Biotechnology · close $432.49 (2026-10-16) · latest quarter in EDGAR: 2026-06-30

#50/150 in sector · #378/964 overall

Amgen (AMGN) has a ThetaGrade House Rating of 58/100 (grade C), ranking #50 of 150 in Health Care. Its strongest pillars are profitability (92) and cash flow (69); its weakest is analyst sentiment (17). TTM revenue growth is 9.1% and operating margin 30.0%.

Data as of 2026-10-16.

Analyst sentiment

weight 7.5% · 17

Consensus score (1–5) (3.8%)	derived	6
90-day net rating shift (3.8%)	derived	10

Growth

weight 30.83% · 61

Revenue growth YoY (TTM) (12.3%)	9.1%	44
EPS growth YoY (TTM) (12.3%)	31.5%	70
Revenue acceleration (6.2%)	3.8%	76

Profitability

weight 18.5% · 92

Operating margin (9.9%)	30.0%	88
4Q gross-margin change (8.6%)	5.0%	96

Balance sheet

weight 18.5% · 35

Net debt / EBITDA (9.9%)	2.61×	37
Current ratio (4.9%)	1.37	23
Interest coverage (3.7%)	4.15×	44

Cash flow

weight 12.33% · 69

FCF margin (6.2%)	22.0%	80
FCF yield (6.2%)	3.5%	57

Valuation

weight 12.33% · 50

P/E (inverted) (6.2%)	26.88×	61
EV/Sales (inverted) (6.2%)	7.27×	38

Technicals (EOD)

RSI(14)	62.5
EMA 9 / 21	421.08 / 414.56
200-day SMA	368.90
Volume vs 20d avg	0.82×
20-day return	13.9%

Exit-rule monitor

EXITRating break: House Rating below 60
WATCHAnalyst drift: net bullish ratings down ≥2 over ~90 days

Data source per metric (SEC XBRL tag or derivation): Revenue: RevenueFromContractWithCustomerExcludingAssessedTax · Gross profit: Revenue − CostOfGoodsAndServicesSold · Operating income: OperatingIncomeLoss · Interest expense: InterestExpenseDebt · D&A: DepreciationDepletionAndAmortization · EPS: EarningsPerShareDiluted · Market cap: SEC shares (dei EntityCommonStockSharesOutstanding (cover page)) × EOD close · P/E: EOD close ÷ SEC TTM EPS (EarningsPerShareDiluted).

Get rating changes like AMGN's in the free Daily Brief

The market’s key events and signals, digested before the open.

✓ Pre-market Daily Brief: events, headlines, rating changes (2-min read)
✓ Sunday: Top 5 Weekly Picks, exit alerts, CSP put watchlist
✓ OPEX, FOMC, CPI and jobs-day reminders

Free. Want more? See Premium (waitlist).

FAQ

What is AMGN's House Rating?: AMGN scores 58 out of 100 (grade C) as of 2026-10-16, ranking #50 of 150 Health Care stocks we cover.
What do analysts say about AMGN?: ThetaGrade's analyst-sentiment pillar for AMGN scores 17/100 against its sector peers, which we read as negative. This is our own derived score; we do not republish individual analyst ratings, counts or targets.
When does AMGN report earnings next?: AMGN's next earnings report is estimated for about 2026-11-03 (window 2026-10-28 to 2026-11-09), based on its past SEC 8-K earnings filings. This is an estimate, not a company-confirmed date.
Is AMGN a buy?: ThetaGrade does not give personal advice. The House Rating is an educational, rules-based summary of public data; see the methodology for how it is built.

Sources: SEC EDGAR filings (fetched 2026-10-18), Finnhub recommendation trends, Massive EOD prices. Scores are sector percentiles; a factor without usable data is a data gap: it is left out and the remaining weights are renormalized (nothing is imputed). Educational only. Methodology